Annual EBITDA
-$506.31 M
-$55.72 M-12.37%
December 31, 2023
Summary
- As of February 8, 2025, NTLA annual EBITDA is -$506.31 million, with the most recent change of -$55.72 million (-12.37%) on December 31, 2023.
- During the last 3 years, NTLA annual EBITDA has fallen by -$376.04 million (-288.66%).
- NTLA annual EBITDA is now -3770.61% below its all-time high of -$13.08 million, reached on December 31, 2015.
Performance
NTLA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$142.16 M
-$5.72 M-4.19%
September 30, 2024
Summary
- As of February 8, 2025, NTLA quarterly EBITDA is -$142.16 million, with the most recent change of -$5.72 million (-4.19%) on September 30, 2024.
- Over the past year, NTLA quarterly EBITDA has dropped by -$13.35 million (-10.36%).
- NTLA quarterly EBITDA is now -12134.25% below its all-time high of -$1.16 million, reached on March 31, 2015.
Performance
NTLA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$527.52 M
-$13.35 M-2.60%
September 30, 2024
Summary
- As of February 8, 2025, NTLA TTM EBITDA is -$527.52 million, with the most recent change of -$13.35 million (-2.60%) on September 30, 2024.
- Over the past year, NTLA TTM EBITDA has dropped by -$50.58 million (-10.60%).
- NTLA TTM EBITDA is now -45297.85% below its all-time high of -$1.16 million, reached on March 31, 2015.
Performance
NTLA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NTLA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.4% | -10.4% | -10.6% |
| 3 y3 years | -288.7% | -102.5% | -136.3% |
| 5 y5 years | -486.0% | -493.7% | -423.4% |
NTLA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -94.0% | at low | -81.0% | +0.2% | -102.2% | at low |
| 5 y | 5-year | -402.4% | at low | -436.5% | +0.2% | -423.4% | at low |
| alltime | all time | -3770.6% | at low | <-9999.0% | +0.2% | <-9999.0% | at low |
Intellia Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$142.16 M(+4.2%) | -$527.52 M(+2.6%) |
| Jun 2024 | - | -$136.44 M(+22.4%) | -$514.18 M(+1.2%) |
| Mar 2024 | - | -$111.49 M(-18.9%) | -$507.90 M(+0.3%) |
| Dec 2023 | -$506.31 M(+12.4%) | -$137.43 M(+6.7%) | -$506.31 M(+6.2%) |
| Sep 2023 | - | -$128.82 M(-1.0%) | -$476.94 M(+5.6%) |
| Jun 2023 | - | -$130.16 M(+18.4%) | -$451.71 M(+8.1%) |
| Mar 2023 | - | -$109.91 M(+1.7%) | -$418.01 M(-7.2%) |
| Dec 2022 | -$450.59 M(+72.7%) | -$108.06 M(+4.3%) | -$450.59 M(+7.0%) |
| Sep 2022 | - | -$103.58 M(+7.4%) | -$421.07 M(+8.6%) |
| Jun 2022 | - | -$96.46 M(-32.3%) | -$387.70 M(+8.1%) |
| Mar 2022 | - | -$142.49 M(+81.4%) | -$358.62 M(+37.4%) |
| Dec 2021 | -$260.96 M(+100.3%) | -$78.53 M(+11.9%) | -$260.96 M(+16.9%) |
| Sep 2021 | - | -$70.21 M(+4.2%) | -$223.22 M(+24.3%) |
| Jun 2021 | - | -$67.38 M(+50.3%) | -$179.51 M(+25.0%) |
| Mar 2021 | - | -$44.83 M(+9.9%) | -$143.60 M(+10.2%) |
| Dec 2020 | -$130.27 M(+29.3%) | -$40.80 M(+54.0%) | -$130.27 M(+10.7%) |
| Sep 2020 | - | -$26.50 M(-15.8%) | -$117.68 M(+2.2%) |
| Jun 2020 | - | -$31.47 M(-0.1%) | -$115.13 M(+4.9%) |
| Mar 2020 | - | -$31.51 M(+11.7%) | -$109.78 M(+8.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$100.78 M(+16.6%) | -$28.20 M(+17.8%) | -$100.78 M(+9.4%) |
| Sep 2019 | - | -$23.95 M(-8.3%) | -$92.09 M(+1.1%) |
| Jun 2019 | - | -$26.12 M(+16.1%) | -$91.10 M(+4.1%) |
| Mar 2019 | - | -$22.51 M(+15.3%) | -$87.50 M(+1.3%) |
| Dec 2018 | -$86.41 M(+29.8%) | -$19.52 M(-14.9%) | -$86.41 M(-4.8%) |
| Sep 2018 | - | -$22.95 M(+1.9%) | -$90.77 M(+9.5%) |
| Jun 2018 | - | -$22.52 M(+5.2%) | -$82.91 M(+9.5%) |
| Mar 2018 | - | -$21.42 M(-10.3%) | -$75.69 M(+13.7%) |
| Dec 2017 | -$66.56 M(+114.3%) | -$23.88 M(+58.3%) | -$66.56 M(+25.4%) |
| Sep 2017 | - | -$15.09 M(-1.4%) | -$53.10 M(+16.8%) |
| Jun 2017 | - | -$15.31 M(+24.6%) | -$45.44 M(+23.4%) |
| Mar 2017 | - | -$12.29 M(+18.0%) | -$36.84 M(+18.6%) |
| Dec 2016 | -$31.05 M(+137.4%) | -$10.42 M(+40.2%) | -$31.05 M(+19.5%) |
| Sep 2016 | - | -$7.43 M(+10.9%) | -$26.00 M(+19.4%) |
| Jun 2016 | - | -$6.70 M(+3.0%) | -$21.77 M(+18.1%) |
| Mar 2016 | - | -$6.51 M(+21.4%) | -$18.43 M(+40.9%) |
| Dec 2015 | -$13.08 M | -$5.36 M(+67.2%) | -$13.08 M(+69.4%) |
| Sep 2015 | - | -$3.21 M(-4.5%) | -$7.72 M(+71.0%) |
| Jun 2015 | - | -$3.35 M(+188.7%) | -$4.52 M(+288.7%) |
| Mar 2015 | - | -$1.16 M | -$1.16 M |
FAQ
- What is Intellia Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Intellia Therapeutics?
- What is Intellia Therapeutics annual EBITDA year-on-year change?
- What is Intellia Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Intellia Therapeutics?
- What is Intellia Therapeutics quarterly EBITDA year-on-year change?
- What is Intellia Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Intellia Therapeutics?
- What is Intellia Therapeutics TTM EBITDA year-on-year change?
What is Intellia Therapeutics annual EBITDA?
The current annual EBITDA of NTLA is -$506.31 M
What is the all time high annual EBITDA for Intellia Therapeutics?
Intellia Therapeutics all-time high annual EBITDA is -$13.08 M
What is Intellia Therapeutics annual EBITDA year-on-year change?
Over the past year, NTLA annual EBITDA has changed by -$55.72 M (-12.37%)
What is Intellia Therapeutics quarterly EBITDA?
The current quarterly EBITDA of NTLA is -$142.16 M
What is the all time high quarterly EBITDA for Intellia Therapeutics?
Intellia Therapeutics all-time high quarterly EBITDA is -$1.16 M
What is Intellia Therapeutics quarterly EBITDA year-on-year change?
Over the past year, NTLA quarterly EBITDA has changed by -$13.35 M (-10.36%)
What is Intellia Therapeutics TTM EBITDA?
The current TTM EBITDA of NTLA is -$527.52 M
What is the all time high TTM EBITDA for Intellia Therapeutics?
Intellia Therapeutics all-time high TTM EBITDA is -$1.16 M
What is Intellia Therapeutics TTM EBITDA year-on-year change?
Over the past year, NTLA TTM EBITDA has changed by -$50.58 M (-10.60%)